You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
醫藥板塊榮辱互見 開拓、和鉑及騰盛升逾6%-10% 國藥探頂 科濟及先聲跌逾6%-7%
市場觀望美國今晚通脹數據,加上港匯逾三個月再度觸及弱方兌換保證,金管局今早於紐約時段入市承接42.23億港元沽盤。港股連續第三天反覆受壓,恆指現報21,121,反覆續跌42點或0.2%,總成交額僅660億元。 醫藥板塊榮辱互見。騰盛博藥-B(02137.HK)由逾五個月高位七連跌後,今早股價反覆再跌4.6%至9.49元(守穩50天線9.07元之上),午後持續抽高兼升破20天線(10.4元),最高見11.16元,現報11元,倒升10.6%,成交增至4,049萬股。開拓藥業-B(09939.HK)兩連升,最高見11.16元,現報10.96元,續升6.4%,成交增至1,275萬股。和鉑醫藥-B(02142.HK)續升逾8%報3.2元,股價突破牛熊線(3.06元)。國藥(01099.HK)三連升兼突破52周高位21.35元,最高見21.9元,創逾15個月高,現報21.65元,續升2.1%。 三葉草生物-B(02197.HK)中午公布重組蛋白新冠疫苗上市並已於浙江長興進行首針接種。該股終止七連跌,股價午後由今早最低位2.27元,掉頭曾一舉升破10天及20天線(2.56元/2.65元),最高見2.94元,現報2.7元,回升13%,成交急增至1.02億股。 然而,藥明生物(02269.HK)料全年多賺三成,野村指該盈喜遜於平均預期,該行下調公司未來三年盈測8.2%/10.2%/9.4%,但維持其「買入」評級。該股今早升1%至65.2元無以為繼,掉頭曾倒跌5.7%,現報62.3元,回吐3.5%。 先聲藥業(02096.HK)未能延續昨天彈勢,股價重失50天線(10.9元),最低見9.98元,現報10.18元,挫7.1%。科濟藥業-B(02171.HK)略高開報18.1元欠承接,掉頭考驗50天線(16.8元),最低見16.54元,現報16.86元,倒跌6.3%。兆科眼科-B(06622.HK)重失20天線(5.33元),最低見5元,現報5.14元,回吐4.5%。諾誠健華-B(09969.HK)三連跌兼失守50天線(13.53元),最低見12.94元,現報13.18元,續跌3.2%。百濟神州(06160.HK)低見144.9元,現報146.8元,跌1.7%。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account